MedTrace Logo

Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer

NCT00002916 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2012-07-02

No results posted yet for this study

Summary

RATIONALE: Vaccines made from human papillomavirus may make the body build an immune response to and kill cervical cancer cells. Combining vaccine therapy with surgery may be a more effective treatment for cervical cancer.

PURPOSE: This phase II trial is studying how well giving vaccine therapy together with surgery works in treating patients with early cervical cancer.

Conditions

Interventions

BIOLOGICAL

human papillomavirus 16 E7 peptide

BIOLOGICAL

synthetic human papillomavirus 16 E6 peptide

PROCEDURE

adjuvant therapy

PROCEDURE

surgical procedure

RADIATION

radiation therapy

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Elaine M. Rankin, MD · Ninewells Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-11-30

Countries

  • Austria
  • France
  • Germany
  • Netherlands
  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002916 on ClinicalTrials.gov